

Vincenzo Serretta

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7816295/vincenzo-serretta-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

712
citations

12
h-index

26
g-index

41
ext. papers

853
ext. citations

2.9
avg, IF

2.98
L-index

#	Paper	IF	Citations
40	Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. <i>Urology</i> , 2002 , 60, 623-7	1.6	174
39	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. <i>European Urology</i> , 2015 , 67, 74-82	10.2	149
38	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 507-514	4	57
37	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. <i>European Urology Oncology</i> , 2018 , 1, 403-410	6.7	41
36	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 484.e19-484.e25	2.8	39
35	Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. <i>Urology</i> , 2005 , 65, 65-9	1.6	36
34	TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. <i>European Urology</i> , 2004 , 45, 730-5; discussion 735-6	10.2	28
33	Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. <i>Urology</i> , 2014 , 84, 1141-6	1.6	27
32	A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2010 , 106, 212-7	5.6	21
31	Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?. <i>Urologia Internationalis</i> , 2016 , 96, 20-4	1.9	18
30	Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma. <i>Urology</i> , 2013 , 81, 277-81	1.6	14
29	A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 174-9	3.3	14
28	Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. <i>Cancer Management and Research</i> , 2018 , 10, 5053-5060	3.6	12
27	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e751-e758	3.3	10
26	Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer. <i>Investigative and Clinical Urology</i> , 2019 , 60, 91-98	1.9	9
25	Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003 , 129, 472-6	4.9	8
24	Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment. <i>Journal of Urology</i> , 2008 , 180, 886-90; discussion 891	2.5	7

23	Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis. <i>Radiologia Medica</i> , 2020 , 125, 220-227	6.5	6
22	Cigarette smoking and drinking water source: correlation with clinical features and pathology of superficial bladder carcinoma. <i>Urologia Internationalis</i> , 2009 , 82, 318-23	1.9	5
21	Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital. <i>Urologia Internationalis</i> , 2009 , 83, 452-7	1.9	5
20	Is KelamiS Method Still Useful in the Smartphone Era? The Virtual 3-Dimensional Reconstruction of Penile Curvature in Patients With PeyronieS Disease: A Pilot Study. <i>Journal of Sexual Medicine</i> , 2021 , 18, 209-214	1.1	4
19	Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT). <i>Pathology Research and Practice</i> , 2017 , 213, 165-169	3.4	3
18	Segmental resection of distal ureter with termino-terminal ureteric anastomosis vs bladder cuff removal and ureteric re-implantation for upper tract urothelial carcinoma: results of a multicentre study. <i>BJU International</i> , 2019 , 124, 116-123	5.6	3
17	Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study. <i>Urologia Internationalis</i> , 2020 , 104, 396-401	1.9	3
16	The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer. <i>Urologia</i> , 2016 , 83, 145-148	1.2	3
15	Management of symptomatic benign prostatic hyperplasia in southern Italy: a retrospective analysis of the Sicilian-Calabrian Society of Urology (SSCU) of 32,000 patients. <i>Urologia Internationalis</i> , 2003 , 71, 16-21	1.9	3
14	Mitomycin C from birth to adulthood. <i>Urologia</i> , 2016 , 83, 2-6	1.2	3
13	Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single-centre open-label uncontrolled trial. <i>Andrologia</i> , 2020 , 52, e13705	2.4	2
12	Clinical pitfalls in diagnosis of nonmuscle-invasive bladder cancer. <i>Urologia</i> , 2015 , 82 Suppl 2, S1-4	1.2	2
11	Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked!. <i>Infectious Diseases</i> , 2015 , 47, 732-3	3.1	1
10	Can We Clinically Distinguish Anejaculation From Retrograde Ejaculation in Patients on 5A-Blockers Therapy for Lower Urinary Tract Symptoms?. <i>Urology</i> , 2020 , 139, 129-133	1.6	1
9	Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. <i>Urology Annals</i> , 2015 , 7, 21-5	1	1
8	Virtual Clinical and Precision Medicine Tumor Boards-Cloud-Based Platform-Mediated Implementation of Multidisciplinary Reviews Among Oncology Centers in the COVID-19 Era: Protocol for an Observational Study (Preprint)		1
7	Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m: A multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 601.e11-601.e16	2.8	1
6	Virtual Clinical and Precision Medicine Tumor Boards-Cloud-Based Platform-Mediated Implementation of Multidisciplinary Reviews Among Oncology Centers in the COVID-19 Era: Protocol for an Observational Study. <i>JMIR Research Protocols</i> , 2021 , 10, e26220	2	1

5	Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 964-969 ^{3.8}		○
4	Sexual dysfunction in dialytic patients. A prospective cross-sectional observational study in two hemodialysis centers. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021 , 93, 215-220	1.6	○
3	A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder cancer not undergoing maintenance after 6-week intravesical prophylaxis. <i>Urologia</i> , 2021 , 3915603211022285	1.2	○
2	Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 1756287221995683	3.2	○
1	Time to safely omit bladder cuff removal for low-risk upper tract urothelial carcinoma. <i>Minerva Urology and Nephrology</i> , 2021 , 73, 417-420	2.3	